Figure 5.
(A) Progression-free survival and (B) overall survival for patients with intrahepatic cholangiocarcinoma treated with the single-agent sorafenib (n=15).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.